Table 1. Clinical Characteristics of 142 Patients Undergoing Hemodialysis Receiving BNT162b2 Vaccine.
| Characteristic | No. (%) | P valuea | ||
|---|---|---|---|---|
| Total (n = 142) | 1 Dose (n = 66) | 2 Doses (n = 76) | ||
| Age, median (IQR), y | 72 (62-79) | 72 (59-76) | 75 (64-82) | .04 |
| Age group | ||||
| ≤55 y | 19 (13) | 10 (15) | 9 (12) | .41 |
| >55 y | 123 (87) | 56 (85) | 67 (88) | |
| Sex | ||||
| Female | 48 (34) | 18 (27) | 30 (39) | .13 |
| Male | 94 (66) | 48 (73) | 46 (61) | |
| Prior COVID-19b | 3 (2) | 1 (2) | 2 (3) | >.99 |
| Positive baseline anti-NPc | 15 (11) | 3 (5) | 12 (16) | .05 |
| Dialysis vintage, median (IQR), y | 2.65 (1.5-4.6) | 2.56 (1.2-4.8) | 2.6 (1.6-4.6) | .81 |
| Cause of end-stage kidney disease | ||||
| Diabetes | 63 (44) | 26 (39) | 37 (49) | .03 |
| Ischemic nephropathy | 27 (19) | 8 (12) | 19 (25) | |
| Glomerulonephritis | 20 (14) | 13 (20) | 7 (9) | |
| Other/unknown | 32 (22) | 19 (29) | 13 (17) | |
| Comorbidities | ||||
| Immunosuppressive treatmentd | 9 (6) | 5 (8) | 4 (5) | .41 |
| Autoimmune disease | 8 (6) | 4 (6) | 4 (5) | .56 |
| Diabetes | 74 (52) | 29 (44) | 45 (59) | .07 |
| Cancer | 23 (16) | 12 (18) | 11 (14) | .36 |
| Coronary artery disease | 53 (37) | 22 (33) | 31 (41) | .62 |
| Congestive heart failure | 37 (26) | 15 (23) | 22 (29) | .36 |
| Chronic obstructive lung disease | 13 (9) | 5 (8) | 8 (11) | .81 |
| Hypertension | 135 (95) | 65 (98) | 70 (92) | .12 |
| Obesitye | 10 (7) | 2 (3) | 8 (11) | .08 |
| Hepatitis B nonresponderf | 11 (8) | 3 (4) | 8 (11) | .16 |
Abbreviations: IQR, interquartile range; NP, nucleocapsid protein.
A t test was used for continuous variables, and χ2 or Fisher exact test was used for categorical variables.
Confirmed using reverse transcriptase polymerase chain reaction.
Determined by enzyme-linked immunosorbent assays with a threshold for positivity at 0.396. The baseline sample was taken before the first dose in the 1-dose group and before the second dose in the 2-dose group.
Defined as using any of the following: antimetabolite agent, calcineurin inhibitor, cytotoxic medications, rituximab in previous 6 months, tumor necrosis factor monoclonal antibodies, or glucocorticoids at doses greater than prednisone, 5 mg/d.
Defined as body mass index greater than 30 (calculated as weight in kilograms divided by height in meters squared).
Defined as hepatitis B surface antibody less than 10 mIU/mL.